華章科技(01673.HK)博榮貸款總協議已告終止
華章科技(01673.HK)就控股股東博榮控股牽涉在一宗爭議中作進一步公布,貸款總協議、博榮與獨立貸款方的抵押總協議及抵押品管理協議均已告終止。
涉嫌未獲授權出售已抵押的800萬股爭議股份中,633.8萬股及106.6萬股已分別於6月6日及6月11日退回博榮的證券戶口,而59.6萬股則經訂約各方同意由獨立貸款方保留以抵銷經紀託管費與獨立貸款方行政費的合計價值。
此外,獨立貸款人及經紀人均不享有退回至博榮證券戶口的740.4萬股爭議股份及保留至證券戶口的約1.23億股已抵押抵押品當中擁有任何擔保權益;及博榮持有合共約4.11億股公司股份,相當於目前公司已發行股本約56.92%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.